Slide 1: Annual General Meeting October 2004
eG COMPUMEDICS RIMITED ‘Defining life’s signals’ Annual General Meeting October 2004
Slide 2: Agenda
“Defining Life’s Signals” C COMPUMEDICS Agenda ® Meeting opens ® Chairman’s address ® Ordinary business # Commendation to John Dyson for his dedication to the Board and his valuable years of service. Special thank you from the Chairman, Board and staff @ Meeting closes
Slide 3: Chairman's Address
“Defining Life’s Signals” C COMPUMEDICS RIMITED Chairman’s Address
Slide 4: Outline
“Defining Life’s Signals” C COMPUMEDICS RIMITED Outline a . Financial highlights — FYE June 30, 2004. Highlights of the past year. w oN DWL acquisition. . Dividends. Key strategies. On es cote Key milestones.
Slide 5: Financial Highlights FYE June 2004: Profit
“Defining Life’s Signals” C COMPUMEDICS Financial Highlights FYE June 2004 °°" PROFIT ® Record, Positive NPAT AUD$2.4M ($3.5m at last year’s FX rates). ® EBITDA grew 55% over the previous year to AUD$2.9M (90% growth to $4.0m at last year’s FX rates) . ® The above results were achieved with the expe
Slide 6: Financial Highlights FYE June 2004: Revenue
“Defining Life’s Signals” C COMPUMEDICS Financial Highlights FYE June 2004 °°" REVENUE ® @ Record revenues of $34m ($39M at last year’s FX rates). Record USA revenues of USD$12.8M. In US dollar terms, USA grew by 35% and Europe by 20% from previous year ended June 2003. Underlying revenue growth was
Slide 7: Financial Highlights FYE June 2004: Cash and Growth
“Defining Life’s Signals” C Financial Highlights FYE June 2004 COMPUMEDICS CASH ® Positive operating and net cash at $2.6m and $1.0m respectively for the year. GROWTH @ Europe business strengthened and is now ready for execution of growth strategy similar to the USA with the building of our sales an
Slide 8: DWL Acquisition
“Defining Life’s Signals” C COMPUMEDICS DWL Acquisition ® European base to underpin growth ® Complementary brain function technology based on Doppler Sonography ® 60% market share in Germany ® Good opportunity to globalise technology ® Incremental sales for 2004/2005 expected to be between AUD4-6 mi
Slide 9: Maiden dividend
“Defining Life’s Signals” C COMPUMEDICS Maiden dividend ® Return - maiden dividend 0.5 cents per share dividend to shareholders declared. @ Reward for patience. ® Confidence in the future. ® Growth into the future off strong technology base. ® Dividend policy. CMP will as it can afford to and it con
Slide 10: Performance relative to PCP
“Defining Life’s Signals” C COMPUMEDICS, Performance relative to PCP 12mthsto | 12mthsto | 12 mths to $Am June 30 June 30 June 30 % change 2002 2003 2004 Operating 19.8 32.1 34.0 6% evenue EBITDA (0.9) 1.9 2.9 55% EBIT (2.4) (18.8) 2.4 nla Profit after Tax (1.9) (18.6) 2.4 nia Gross Margin 64% 57% 5
Slide 11: Balance Sheet relative to PCP
“Defining Life’s Signals” C COMPUMEDICS Balance Sheet relative to PCP sons June 2004 June 2003 A$’000 A$’000 CURRENT ASSETS Cash assets 6,352 5,366 Receivables 10,239 8,624 Inventories 6,481 8,416 Other 69 180 Total current assets 23,141 22,586 NON CURRENT ASSETS Property, plant and equipment 1,368
Slide 12: Financial Performance
“Defining Life’s Signals” C COMPUMEDICS Financial Performance tenes ® Underlying operating earnings ~ Growth and efficiencies have significantly contributed to earnings. This has resulted in a positive shift in EBITDA to $2.1m ® Costs under focus ~ Critical mass in place, earnings continue to grow ~
Slide 13: Historical Sales Graph
“Defining Life’s Signals” ; : COMPUMEDIS Historical Sales Graph AU$m 30, 254 20; "95 '96 ‘97 ‘98 '99 ‘00 ‘O01 ‘02 ‘03 ‘04 Export Sales & Domestic Sales H Other Income
Slide 14: International expansion gains momentum
“Defining Life’s Signals” Cc COMPUMEDICS LIMITED International expansion gains momentum 2001 2002 2003 2004 BM Asia O Europe Australia QUSA
Slide 15: Global Brain Research and Global Sleep Diagnostics
‘Defining Life’s Signals” COMPUMEDICS ITED Global Brain Research Global Sleep D
Slide 16: Strategy Working
“Defining Life’s Signals” C COMPUMEDICS Strategy Working = Building a global medical diagnostic company ® With Compumedics’ core strategic edge being Sleep Diagnostics and ® Leveraging this technology into related fields including Neurosciences and Cardiology.
Slide 17: Moving Forward: Business
“Defining Life’s Signals” C COMPUMEDICS Moving Forward : Business wis o Revenues expected to be between $42million and $48million for year ended June 30, 2005. Earnings after tax expected to be between $3 million and $4 million for year ended June 30, 2005. Revenue in the second half expected to be
Slide 18: Moving Forward: Technologies
“Defining Life’s Signals” C COMPUMEDICS Moving Forward : Technologies wines ® Strong product pipelines in all CMP divisions. ® Medical Innovation breakthroughs now approaching patent and clinical proof of concept phase.
Slide 19: Recap
“Defining Life’s Signals” C COMPUMEDICS Recap vee Returned to profitability at $2.4M. Positive cash position. Sales growth strong. Big boost in operational efficiency and more to come. Strong product pipeline and Medical innovation breakthroughs on the horizon. USA continues to grow strongly (USA gr
Slide 20: Ordinary business
“Defining Life’s Signals” C COMPUMEDICS Ordinary business ® Election of Director. ® Mr. John Dyson who retires by rotation does not offer himself for re-election to the position of Non-Executive Director. ® Mr. Bruce Rathie is nominated to the position of Non- Executive Director and offers himself f
Slide 21: End of Business
“Defining Life’s Signals” C COMPUMEDICS RIMITED EURO WED) End of Business Annual General Meeting October 2004